• Dementia/Alzheimer’s and Parkinson’s DDx patients

• Oral, NPC, H&N, and cervical cancer patients

• PET novel drug trial subjects

• PET research collaborators

• Animal imaging research subjects

Linkou Chang Gung Memorial Hospital Molecular Imaging Center, led by Director Tzu-Chen Yen, built the "Locomotive of Biomedical Technology." Team comprises 10 physicians (1 professor, 1 associate, 4 assistant, 2 lecturers, 1 general, 1 physician-scientist), 6 radiologic technologists (2 master's), 2 cyclotron operators, 1 medical physicist, 5 researchers (1 master's, 4 PhDs), 4 joint associate researchers. Equipment: 2 PET scanners, 2 cyclotrons; animal imaging lab with Animal SPECT/CT, Animal PET, 7T Animal MRI. Development areas: center-initiated, collaborated, and core service imaging projects. Safety & Quality: USA Clinical Trials Network certified institution; in-house redesigned Sumitomo synthesizer for 18F-AV133 (Parkinson's) and 18F-AV45 (dementia) synthesis modules—world-first. Clinical features: (1) Oral cancer research changed US AJCC cancer staging guidelines (Cancer 2006, Oral Oncol 2007); (2) NPC research changed US NCCN 2006 treatment guidelines; (3) Cervical & H&N cancer research changed US CMS reimbursement standards. PET targeted novel drugs: 18F-AV-45 (FDA-approved Amyvid for dementia), 18F-AV-133 (earliest worldwide for Parkinson's), 18F-RGD-K5 (world first-in-human study in H&N cancer, with Siemens/PETNET). PubMed 2003-2012: 94 publications (exceeds Peking Union 21, U Tokyo 55, Cambridge 102, MD Anderson 95).

• World-first 18F-AV133/AV45 synthesis modules

• In-house redesigned Sumitomo synthesizer

• Changes US AJCC/NCCN/CMS guidelines

• Founded Taiwan ADNI (T-ADNI)

• Joined worldwide-ADNI

• World first-in-human 18F-RGD-K5 study

• 10 physicians, 6 radiologic technologists, 5 researchers

• 2 PET scanners, 2 cyclotrons

• Animal imaging lab (SPECT/CT, PET, 7T MRI)

• PubMed 2003-2012: 94 papers

• USA CTN certified institution

• Eli Lilly, Siemens, PETNET collaboration

• World-leading publications (94 vs PUMCH 21, U Tokyo 55, MD Anderson 95)

• Dementia AV-45: 23% of global papers

• Parkinson AV-133: 31% of global papers

• NPC molecular imaging: 22% of global

• Cervical cancer 21 papers (10% global)

• 18F-AV45 FDA approved (Amyvid)

• Comprehensive cyclotron QC

• Stable 18F operating efficiency

• USA Clinical Trials Network certification

• Complete standardized SOPs

• Animal trials (GLP) to human Phase II

• Cross-disciplinary QA collaboration

• Wide research-community adoption

• Cooperation with Eli Lilly, Siemens, PETNET

• Tech transfer with NHRI, ITRI

• Improved patient differential diagnosis accuracy

• 10+ international media reports

• Multiple international patents

• PubMed 2003-2012: 94 papers, world-leading

• Changed US AJCC, NCCN, CMS guidelines

• Co-developed FDA-approved Amyvid with Eli Lilly

• Joined worldwide-ADNI consortium

• Mutual Recognition agreement with USA PETNET

• Multiple international patents & industry collaborations

• Comprehensive translational research integration (oral cancer model)

• Cooperation with 13 medical centers/universities globally

• Drives Focused Ultrasound brain drug delivery

• Innovative company tech transfer with CGU, NTHU, NHRI, ITRI

• CGU-NTHU nano & tissue engineering team

• Building world's first comprehensive PET/MRI translational research center